Advance approaches in alopecia

Anand mohan, Mohd. Adil Khan, Suresh Chandra


Alopecia is characterized by hair loss mainly on scalp some time on other resign of the body that has negative psychological and social impact on patients. Androgenetic alopecia and alopecia areata are common disorders. Androgenetic alopecia is the sensitivity of scalp follicles to dihydrotestosterone and alopecia areata is an autoimmune disorder. Current studies have explained the efficacy of corticosteroid therapy or the combination of ultraviolet A therapy and systemic corticosteroids for severe AA. Finasteride opens up new possibilities for the treatment of androgenetic alopecia. Current drug treatment approaches use regrowth stimulators such as minoxidil and finasteride for androgenetic alopecia, as well as corticosteroids, PUVA therapy for alopecia areata. Targeted delivery to the Hair follicle units helps faster targeting to cells that accelerate drug action by faster availability of drug, novel combination treatments combinations like tretinoin with minoxidil shows better results, gene therapy are new approaches that are under developing stage and giving satisfactory results on animal as well as humans.


Minoxidil, Finasteride, Targeted delivery, Nanostructured lipid carrier, Gene therapy

Full Text:



Ito T. Recent advances in the pathogenesis of autoimmune hair loss Disease alopecia areata. Hindawi publishing corporation clinical and developmental immunology. 2013;348546:1-6.

Amin SS, Sachdeva S. Alopecia areata: A review. J Saudi Society Dermatol Dermatologic Surg. 2013;17:37-45.

França K, Rodrigues TS, Ledon J, Savas J, Chacon A. Comprehensive Overview and Treatment Update on Hair Loss. J Cosmetics, Dermatological Sci Applications. 2013;3:1-8.

Alkhalifah A, Alsantali A, Wang E, McElwee KJ, Shapiro J. Alopecia areata update. Part I. Clinical picture, histopathology, and pathogenesis. J Am Acad Dermatol. 2010;62(2):177–88.

Kligman AM. The Human Hair Cycle. J Investigative Dermatol. 1959;33:307-16.

Harrison S, Sinclair R. Telogen Effluvium. Clin Experimental Dermatol. 2002;27(5):389-95.

Kligman A. Pathological Dynamics of Reversible Hair Loss in Humans. Arch Dermatol. 1961;83:175-98.

Cash TF, Price VH, Savin RC. Psychological effects of androgenetic alopecia on women: comparisons with balding men and with female control subjects. J Am Acad Dermatol. 1993;29:568–75.

Ohyama M. Management of hair loss diseases. Dermatologica sinica. 2010;28(4):139–45.

British association of dermatologists patient information leaflet produced may 2007 updated may 2010, august 2013, October 2016 review date October 2019.

Cafardi J. The manual of dermatology. Springer. 2012;8:573.

Kurata S, Uno H, Allen-Hoffmann BL. Effects of hypertrichoticagents on follicular and nonfollicular cells in vitro. Skin Pharmacol 1996;9:3-8.

Michelet JF, Commo S, Billoni N, Mahé YF, Bernard BA. Activation of cytoprotectiveprostaglandin synthesase-1 by minoxidil as a possibleexplanation for its hair growth-stimulating effect. J Invest Dermatol 1997;108(2):205-9.

Shapiro J, Price VH. Hair regrowth: therapeutic agents. Dermatol Clin. 1998;16(2):341-56.

Meidan VM, Touitou E. Treatments for androgenetic alopecia and alopecia areataCurrent options and future prospects. Drugs. 2001;61:53-69.

Philpott M, Sanders D, Kealy T. Whole follicular culture. Dermatol Clin 1996;14:595-607.

Olsen E. Androgenetic alopecia. Disordersof hair growth. New York: McGraw-Hill Inc; 1994: 257.

Dallob A, Sadick N, UngerW. The effect of finasteride, a5αreductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male patternbaldness. J Clin Endocrinol Metab. 1994;79:703-6.

Kaufman K. Clinical studies on the effects of oral finasteride, atype II 5α-reductase inhibitor, on scalp hair in men with malepattern baldness. In: Van Nesteb D, Randall V, editors. Hairresearch for the next millenium. Amsterdam: Elsevier Science; 1996: 363.

Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, et al. Finasteride in thetreatment of men with androgenetic alopecia: FinasterideMale Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998;39:578-89.

Greenberg JH, Katz M. Treatment of androgeneticalopeciawitha 7.5% herbal preparation. J Dermatol Treat. 1996;7:159-62.

Price VH. Rogaine (topical minoxidil) in the management ofmale-pattern baldness and alopecia areata: summary. J Am Acad Dermatol 1987;16:749-50.

Pericin H, Trueb RM. Topical immunotherapy of severe alopeciaareata with diphenylcyclopropenone: evaluation of 68cases. Dermatol. 1998;196:418-21.

Shapiro J. Alopecia areata. Dermatol Clin. 1993;11:35-40.

Rushton DH. Nutritional Factors and Hair Loss. Clin Experimental Dermatol. 2002;27(5):396-404.

Boccaletti V, Zendri E, Giordano G, Gnetti L, De Panfilis G. Familial Uncombable Hair Syndrome: Ul- trastructural Hair Study and Response to Biotin. Pediatr Dermatol. 2007;24(3):E14-6.

Shelley WB, Shelley D. Uncombable Hair Syndrome: Observations on Response to Biotin and Occurrence in Siblings with Ectodermal Dysplasia. J Am Acad Dermatol. 1985;13(1):97-102.

Mccoy A, Ziering C. Botanical extracts for the treatment of androgeneticAlopecia. Int J Life Sci Pharma Res. 2012;2:31-8.

Oh GN, Son SW. Efficacy of Korean Red Ginseng in the Treatment of Alopecia Areata. J Ginseng Res. 2012;36:391-5.

Khidhir1 KG, Mahmood KI. The effects of traditional kurdistan plant extracts on rat hair growth in vivo. Int J Scientific Res Publicat. 2016;6:450-4.

Jaybhaye D, Varma S, Gagne N, Bonde V, Gite A, Bhosle D. Effect of tectonagrandislinn. Seeds on hair growth activity of albino mice. Int J Ayurveda Res. 2010;4:211-5.

Uprit S, Sahu RK, Roy A, Pare A. Preparation and characterization of minoxidil Loaded nanostructured lipid carrier gel for effective Treatment of alopecia. Saudi Pharm J. 2013;21:379-85.

Kashyap R, Shukla K, Mahajan SC, Sharma A. Formulation and evaluation of hair oil for hair loss disorders. 2016;4(3):13-7.

Meena AK, Singh U, Yadav AK, Singh B, Rao MM. Pharmacological and phytochemical evidences for the extracts from plants of the genus vitex – a review. Int J Pharma Clin Res. 2010;2(1):1-9.



  • There are currently no refbacks.

Copyright (c) 2017 Pharmaceutical and Biological Evaluations

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Creative Commons License


© Copyright 2018 - Pharmaceutical and Biological Evaluations